Christos Georgiades
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christos Georgiades has a total of 238 co-authors. Here are the top co-authors by number of shared publications:
- Kelvin Hong
Johns Hopkins Hospital, Interventional Radiology Center
20 shared publications - Mark Yarchoan
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
13 shared publications - Amy K. Kim
Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, USA
12 shared publications - Christopher R. Shubert
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
12 shared publications - Jeffrey Meyer
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
12 shared publications - Jin He
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
12 shared publications
Latest Publications
- 7 July 2026
- Published by Springer Nature in Emergency Radiology
- Vol. 33 (5) , 1219-1232
CTA-positive, angiography-negative lower GI bleeding: an institutional imaging-guided management algorithm
Gastrointestinal bleeding is a common acute presentation in the emergency department (ED) that may require immediate, life-saving intervention. Lower gastrointestinal bleeding (LGIB) represents a frequent source of high-acuity ED presentations, requiring time-sensitive decisions regarding imaging selection, level of care, transfusion strategy, and subspecialty consultation. In such cases, rapid diagnosis and hemodynamic assessment are crucial and facilitated by a multimodal diagnostic approach. Colonoscopy, nuclear medicine studies, and cross-sectional imaging are well-established modalities for evaluating LGIB, with computed tomography angiography (CTA) rapidly emerging as a first-line diagnostic tool, particularly in hemodynamically unstable patients. When active extravasation is identified on CTA, patients are often referred for transcatheter angiography (TA) to enable localization and potential endovascular intervention. However, ambiguity remains regarding the appropriate management of cases in which active hemorrhage is identified on CTA but not reproduced on TA. This discordance may reflect the intermittent nature of hemorrhage, temporal delays between imaging and intervention, or differing detection thresholds across modalities, creating a significant diagnostic and therapeutic dilemma for emergency, gastroenterology, and interventional radiology teams involved in the acute management of LGIB. We propose an institutional, imaging-guided management strategy for patients with CTA-positive but angiography-negative LGIB, emphasizing a tiered approach that prioritizes conservative management with arterial sheath retention, followed by provocative angiography, and selective use of colonoscopy. These strategies are not applied in a rigid or sequential manner but rather represent complementary options that are selectively employed based on hemodynamic status, clinical trajectory, transfusion requirements, and evidence of ongoing or recurrent bleeding.
- 7 July 2026
- Published by Springer Nature in Emergency Radiology
- Vol. 33 (5) , 1219-1232
CTA-positive, angiography-negative lower GI bleeding: an institutional imaging-guided management algorithm
Gastrointestinal bleeding is a common acute presentation in the emergency department (ED) that may require immediate, life-saving intervention. Lower gastrointestinal bleeding (LGIB) represents a frequent source of high-acuity ED presentations, requiring time-sensitive decisions regarding imaging selection, level of care, transfusion strategy, and subspecialty consultation. In such cases, rapid diagnosis and hemodynamic assessment are crucial and facilitated by a multimodal diagnostic approach. Colonoscopy, nuclear medicine studies, and cross-sectional imaging are well-established modalities for evaluating LGIB, with computed tomography angiography (CTA) rapidly emerging as a first-line diagnostic tool, particularly in hemodynamically unstable patients. When active extravasation is identified on CTA, patients are often referred for transcatheter angiography (TA) to enable localization and potential endovascular intervention. However, ambiguity remains regarding the appropriate management of cases in which active hemorrhage is identified on CTA but not reproduced on TA. This discordance may reflect the intermittent nature of hemorrhage, temporal delays between imaging and intervention, or differing detection thresholds across modalities, creating a significant diagnostic and therapeutic dilemma for emergency, gastroenterology, and interventional radiology teams involved in the acute management of LGIB. We propose an institutional, imaging-guided management strategy for patients with CTA-positive but angiography-negative LGIB, emphasizing a tiered approach that prioritizes conservative management with arterial sheath retention, followed by provocative angiography, and selective use of colonoscopy. These strategies are not applied in a rigid or sequential manner but rather represent complementary options that are selectively employed based on hemodynamic status, clinical trajectory, transfusion requirements, and evidence of ongoing or recurrent bleeding.
- 6 May 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (11) , 1-17
Recent developments and prospects in locoregional therapy of hepatocellular carcinoma
This invited review discusses recent advancements and prospects in locoregional therapy (LRT) for hepatocellular carcinoma (HCC), a leading cause of cancer mortality globally. The epidemiology of HCC is shifting toward nonviral etiologies, prompting a focus on early surveillance and personalized treatment approaches. Updated international guidelines, such as the Barcelona Clinic Liver Cancer (BCLC) staging system, American Association for Study of Liver Disease (AASLD) guideline, and European Association for the Study of the Liver (EASL) now recognize LRT—including transarterial embolization, ablation, and radiotherapy—as cornerstone therapies in curative and downstaging strategies for HCC at multiple stages. The article reviews novel transarterial and ablative technologies, including advanced dosimetry for radioembolization, innovative embolic agents, and emerging nonthermal ablation modalities like irreversible electroporation and pulsed electric field ablation, all aimed at increasing precision, local delivery, minimizing systemic exposure. Additionally, combination approaches integrating LRT with immunotherapy are highlighted, reflecting the evolving understanding of HCC’s tumor-immune microenvironment. Progress in robotic guidance, fusion imaging, and imageable radioembolics is also explored. Ongoing and future clinical trials will further define the optimal use of these evolving modalities. Overall, LRT continues to expand as a minimally invasive, indispensable backbone in multidisciplinary HCC management.
- 6 May 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (11) , 1-17
Recent developments and prospects in locoregional therapy of hepatocellular carcinoma
This invited review discusses recent advancements and prospects in locoregional therapy (LRT) for hepatocellular carcinoma (HCC), a leading cause of cancer mortality globally. The epidemiology of HCC is shifting toward nonviral etiologies, prompting a focus on early surveillance and personalized treatment approaches. Updated international guidelines, such as the Barcelona Clinic Liver Cancer (BCLC) staging system, American Association for Study of Liver Disease (AASLD) guideline, and European Association for the Study of the Liver (EASL) now recognize LRT—including transarterial embolization, ablation, and radiotherapy—as cornerstone therapies in curative and downstaging strategies for HCC at multiple stages. The article reviews novel transarterial and ablative technologies, including advanced dosimetry for radioembolization, innovative embolic agents, and emerging nonthermal ablation modalities like irreversible electroporation and pulsed electric field ablation, all aimed at increasing precision, local delivery, minimizing systemic exposure. Additionally, combination approaches integrating LRT with immunotherapy are highlighted, reflecting the evolving understanding of HCC’s tumor-immune microenvironment. Progress in robotic guidance, fusion imaging, and imageable radioembolics is also explored. Ongoing and future clinical trials will further define the optimal use of these evolving modalities. Overall, LRT continues to expand as a minimally invasive, indispensable backbone in multidisciplinary HCC management.
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (3) , e260355
Microwave Ablation for Colorectal Liver Metastases: If Your Margin Is Less than 10 mm, Your Intention Is Not Curative
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (3) , e260355
Microwave Ablation for Colorectal Liver Metastases: If Your Margin Is Less than 10 mm, Your Intention Is Not Curative
- 1 January 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (1) , e253806
Intrahepatic Cholangiocarcinoma: Local-Regional Therapies Join the Fight
- 1 January 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (1) , e253806
Intrahepatic Cholangiocarcinoma: Local-Regional Therapies Join the Fight
- Open Access
- 10 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6391
Surgery Without Scalpel: Histotripsy as a Non-Invasive and Non-Thermal Modality for Liver Tumor Ablation
Liver malignancies are among the most prevalent cancers worldwide and can be managed using various therapeutic approaches. However, the available options for treating these malignancies are characterized by several limitations. Histotripsy, which was recently approved by the Food and Drug Administration (FDA), seems to be promising for overcoming these limitations. It is an emerging non-invasive, non-thermal ultrasound technology, which is based on the controllable initiation of cavitation from endogenous nanometer-scale gas pockets within tissues. Numerous preclinical studies as well as three clinical studies highlight this technique as feasible, safe, and effective. Among its advantages are the lack of thermal injury, its non-invasive nature, its immunopreserving and possibly immunostimulating ability, as well as the low number of complications that accompany it. Nonetheless, long-term clinical outcomes are still lacking, and further studies are needed to establish its definitive role in liver cancer treatment. In conclusion, histotripsy shows strong potential to become a transformative tool in liver oncology, but continued clinical evaluation is essential to validate its long-term efficacy and integration into standard care.
- 10 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6391
Open AccessSurgery Without Scalpel: Histotripsy as a Non-Invasive and Non-Thermal Modality for Liver Tumor Ablation
Liver malignancies are among the most prevalent cancers worldwide and can be managed using various therapeutic approaches. However, the available options for treating these malignancies are characterized by several limitations. Histotripsy, which was recently approved by the Food and Drug Administration (FDA), seems to be promising for overcoming these limitations. It is an emerging non-invasive, non-thermal ultrasound technology, which is based on the controllable initiation of cavitation from endogenous nanometer-scale gas pockets within tissues. Numerous preclinical studies as well as three clinical studies highlight this technique as feasible, safe, and effective. Among its advantages are the lack of thermal injury, its non-invasive nature, its immunopreserving and possibly immunostimulating ability, as well as the low number of complications that accompany it. Nonetheless, long-term clinical outcomes are still lacking, and further studies are needed to establish its definitive role in liver cancer treatment. In conclusion, histotripsy shows strong potential to become a transformative tool in liver oncology, but continued clinical evaluation is essential to validate its long-term efficacy and integration into standard care.
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (1) , e250797
Adrenal Vein Sampling: The Value of Multisampling and Adrenocorticotropic Hormone Stimulation and a Call to Arms
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (1) , e250797
Adrenal Vein Sampling: The Value of Multisampling and Adrenocorticotropic Hormone Stimulation and a Call to Arms
- 1 March 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 314 (3) , e241430
CT-guided Percutaneous Ethanol Sympatholysis for Hyperhidrosis: How I Do It
CT-guided percutaneous ethanol sympatholysis provides 60% long-term effectiveness for facial, axillary, and/or palmar hyperhidrosis (excessive sweating of the face, armpits, and hands); although it comes with a 15% risk of compensatory hyperhidrosis elsewhere in the body, it can be a life-altering intervention for those with severe disease.
- 1 March 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 314 (3) , e241430
CT-guided Percutaneous Ethanol Sympatholysis for Hyperhidrosis: How I Do It
CT-guided percutaneous ethanol sympatholysis provides 60% long-term effectiveness for facial, axillary, and/or palmar hyperhidrosis (excessive sweating of the face, armpits, and hands); although it comes with a 15% risk of compensatory hyperhidrosis elsewhere in the body, it can be a life-altering intervention for those with severe disease.
- Open Access
- 26 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
S1. Flow diagram depicting inclusion and exclusion criteria for current study
- 26 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
S1. Flow diagram depicting inclusion and exclusion criteria for current study
- Open Access
- 26 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
S1. Flow diagram depicting inclusion and exclusion criteria for current study
- 26 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
S1. Flow diagram depicting inclusion and exclusion criteria for current study
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (3) , e242012
From Echoes to Disruption: US from Diagnostic Imaging to Precision Therapeutic Modality
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (3) , e242012
From Echoes to Disruption: US from Diagnostic Imaging to Precision Therapeutic Modality